Non-invasive prenatal testing (NIPT) is a   screening method used to assess the risk  of   certain  genetic conditions in a fetus, such  as  Down  syndrome, by analyzing cell-free DNA from the  mother's     blood. This test is typically performed   after   10 weeks   of pregnancy and poses no risk to the fetus, making  it non-invasive.    NIPT       analyzes    the    fetal  DNA circulating in    the    maternal bloodstream to detect chromosomal abnormalities. It is highly accurate for conditions like trisomy 21 (Down syndrome), trisomy 18, and trisomy    13.  Although      NIPT   is      highly reliable, it is a screening, not a  diagnostic test.      A positive result usually leads to   further confirmatory testing, like amniocentesis. NIPT   is becoming more widely available and is   often   preferred    due to its high sensitivity and safety.